I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Find a Research Lab
Atul Bedi Lab
The Atul Bedi Lab in the Head and Neck cancer research program provides fundamental insights into the molecular determinants and mechanisms by which tumor cells evade death signals entrained by the immune system and anticancer agents. Their recent studies show that tumor-induced immune tolerance limits the in vivo anti-tumor efficacy of tumor-targeted antibodies and that the tumor cell-autonomous expression of transforming growth factor-b (TGF-b) is a key molecular determinant of the de novo or acquired resistance of cancers to EGFR-targeted antibody. Their laboratory has developed novel bi-functional antibody-based strategies to simultaneously counteract immune tolerance in the tumor microenvironment and to enhance the anti-tumor efficacy of targeted antibody therapies for the treatment of cancer.
The Brennen laboratory takes a rigorous, multi-disciplinary, team-based approach towards developing innovative therapeutic and prognostic strategies for prostate cancer with an emphasis on exploiting vulnerabilities within the tumor microenvironment towards this goal. To accomplish this goal, we are strategically pursuing novel therapeutic platforms, including stromal-targeted prodrugs, protoxins, and radiolabeled antibodies, in addition to cell-based therapy and drug delivery; all of which are designed to reduce toxicity to peripheral non-target tissue (i.e. side effects) while maximizing anti-tumor efficacy (i.e. therapeutic benefit). Currently, many of these strategies are focused on overcoming stromal barriers to anti-tumor immune responses such that men suffering from prostate cancer can share in the immense, revolutionary power of immunotherapy that is transforming care for many with advanced disease in other tumor types previously thought to be unmanageable using conventional ap...proaches. Unfortunately, prostate cancer has largely proven refractory to these powerful approaches thus far and requires novel mono- or combinatorial treatment strategies to unleash the full potential of the immune system and generate personalized anti-tumor responses with the capability of producing long-term durable responses or even cures in these men. view more
The Erika Darrah Lab is primarily interested in the mechanisms underlying the development and progression of autoimmunity in rheumatoid arthritis (RA), with a particular focus on the peptidyl arginine deiminase (PAD) enzymes. We’re focused on understanding the development of PAD4-activating autoantibodies over time and how they contribute to the development of erosive disease. Studies are underway to determine if the newly discovered antibody is mimicking a naturally occurring PAD4 binding partner and to identify potentially pro-inflammatory effects of citrullinated proteins on effector cells of the immune system.
Esther Oh Lab
The Esther Oh Lab is interested in developing biological markers for pre-clinical stages of Alzheimer's disease (AD). Our current research involves using transgenic models of AD to develop peripheral injections of monoclonal antibodies against amyloid-beta as a tool to detect a level of amyloid-beta that would be correlative to the amyloid-beta level in the brain.
Mary Philogene Lab
Research in the Mary Philogene Lab focuses on the field of histocompatibility and transplant immunology. Our studies in immunogenetics have included topics such as immunologic risk factors in transplant patients, the role of non-HLA antibodies in primary graft dysfunction following cardiac transplantation, and immunosuppression withdrawal and allograft function in pediatric liver transplant recipients.
Nada Alachkar Lab
Dr. Alachkar's research focuses on recurrent glomerular diseases post kidney transplantation. In particular, she has been studying recurrent FSGS post kidney transplant in several, partially NIH funded, prospective research projects that focuses on circulating factors associate with recurrent FSGS and new therapies of recurrent FSGS; in addition to the outcome of the disease. Also, Dr. Alachkar is the Chair of Banff recurrent GN working group that focus on the pathological changes of recurrent GN.
Dr. Alachkar's other research focus is incompatible living and diseases donor transplant. She has several ongoing research studies that focus on AMR and the outcome of patients with positive donor specific antibodies.
We are devoted to developing and deploying cutting edge technologies that can be used to define human immune responses. Much of our work leverages ‘next generation’ DNA sequencing, which enables massively parallel molecular measurements. Examples of our technologies include:
- bacteriophage display of synthetic peptidome libraries for comprehensive, quantitative profiling of antibodies;
- display of ORFeome libraries for antigen discovery, protein-protein interaction studies, and drug target identification;
- ultrasensitive, multiplex RNA quantification techniques to monitor gene expression and detect microbes;
- pooled genetic screening to elucidate immune cell function and identify new therapeutic targets.
The Larman Laboratory uses these and other approaches to identify opportunities for monitoring and manipulating immune responses.
The Vascularized Composite Allotransplantation (VCA) Research Lab is leading research aimed at warding against rejection and reducing the number of medications patients have to take for the rest of their lives. They’re testing a protocol that involves treating the patient with antibodies on the day of transplant, followed by a donor bone marrow infusion several days later. This protocol would allow patients to be treated with low doses of a single maintenance drug after being transplanted.
Thomas Grader-Beck Lab
Research in the Thomas Grader-Beck Lab aims to understand the pathogenesis of systemic autoimmune diseases—particularly systemic lupus erythematosus (SLE) and Sjögren’s syndrome—by taking a translational approach. Autoantibodies (antibodies that target self-molecules) are believed to contribute significantly to the disease process. We are studying mechanisms that may make self-structures immunogenic. We theorize that certain post-translational antigen modifications, which can occur in infections or malignant transformation, result in the expression of neoepitopes that spread autoimmunity in the proper setting. The team has combined studies that employ a number of mouse strains, certain gene-deficient mice and human biological specimens.